Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139256 | 0.87 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| SCHEMBL11420225 | 0.86 | ADRB3 (0.61) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| Amidephrine Mesylate SCHEMBL122479 | 0.84 | ADRB3 (0.58) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| Hydrochloric Acid SCHEMBL9216885 | 0.84 | ADRB3 (0.59) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| Hydrochloric Acid SCHEMBL9216889 | 0.84 | ADRB3 (0.59) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| SCHEMBL6074523 | 0.83 | LMNA (0.65) | ALDH1A1SMN1; SMN2ADRA1AADRA2CADRA1B | |
| SCHEMBL9447441 | 0.83 | LMNA (0.65) | ALDH1A1SMN1; SMN2ADRA1AADRA2CADRA1B | |
| SCHEMBL6075074 | 0.83 | LMNA (0.65) | ALDH1A1SMN1; SMN2ADRA1AADRA2CADRA1B | |
| Amidephrine Mesylate SCHEMBL122478 | 0.83 | ADRB3 (0.56) | ALDH1A1SMN1; SMN2POLBADRA1AADRA2C | |
| SCHEMBL245468 | 0.81 | MEN1 (0.60) | ALDH1A1SMN1; SMN2POLBKEAP1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | ALDH1A1 1815/4885SMN1; SMN2 4763/4885POLB 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.